Portal de Periódicos da CAPES

Clinical Trials of Irinotecan Hydrochloride (CPT, Campto Injection, Topotecin Injection) in Japan a

1996; Wiley; Volume: 803; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1996.tb26399.x

1749-6632

Nagahiro Saijo,

Neutropenia and Cancer Infections

Annals of the New York Academy of SciencesVolume 803, Issue 1 p. 292-305 Clinical Trials of Irinotecan Hydrochloride (CPT, Campto Injection, Topotecin Injection) in Japana NAGAHIRO SAIJO, NAGAHIRO SAIJO National Cancer Center, Research Institute and Hospital Tsukiji 5-1-1, Chuo-ku Tokyo 104, JapanSearch for more papers by this author NAGAHIRO SAIJO, NAGAHIRO SAIJO National Cancer Center, Research Institute and Hospital Tsukiji 5-1-1, Chuo-ku Tokyo 104, JapanSearch for more papers by this author First published: December 1996 https://doi.org/10.1111/j.1749-6632.1996.tb26399.xCitations: 18 a Supported in part by Grants-in-Aid for Cancer Research from the Ministry of Health and Welfare, the second term of the Comprehensive Ten-Year Strategy for Center Control, Ministry of Education, Science and Culture. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Matsuzaki, T., T. Yokokura, M. Mutai & T. Tsuruo. 1988. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol. 21: 308–312. 2 Kaneda, N., H. Nagata, T. Furuta & T. Yokokura. 1990. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50: 1715–1720. 3 Kanzawa, F., Y. Sugimoto, K. Minato, K. Kasahara, M. Bungo, K. Nakagawa, T. Fujiwara, L. F. Liu & N. Saijo. 1990. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance. Cancer Res. 50: 5919–5924. 4 Taguchi, T., A. Wakui, K. Hasegawa, H. Niitani, H. Furue, K. Ohta & T. Hattori. 1990. Phase I clinical study of CPT-11. Jpn. J. Cancer Chemother. 17: 115–120. 5 Negoro, S., M. Fukuoka, N. Masuda, M. Takada, Y. Kusunoki, K. Matsui, N. Takifuji, S. Kudoh, H. Niitani & T. Taguchi. 1991. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 83: 1164–1168. 6 Fukuoka, M. & M. Masuda. 1994. Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother. Pharmacol. 34: S105–S111. 7 Fukuoka, M., H. Niitani, A. Suzuki, M. Motomiya, K. Hasegawa, Y. Nishiwaki, T. Kuriyama, Y. Ariyoshi, S. Negoro, N. Masuda, S. Nakajima & T. Taguchi, for the CPT-11 Lung Cancer Study Group. 1992. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J. Clin. Oncol. 10: 16–20. 8 Masuda, N., M. Fukuoka, Y. Kusunoki, K. Matsui, N. Takifuji, S. Kudoh, S. Negoro, M. Nishioka, K. Nakagawa & M. Takada. 1992. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J. Clin. Oncol. 10: 1225–1229. 9 Society of Japanese Pharmacopoeia. 1995. Summary Basis of Approval (SBA) No. 1. Irinotecan hydrochloride (Campto injection, Topotecin injection)., Yakuji Nippo, Ltd. 10 Shimada, Y., M. Yoshino, A. Wakui, I. Nakao, K. Futatsuki, Y. Sakata, M. Kambe, T. Taguchi, M. Ogawa & The CPT-11 Gastrointestinal Cancer Study Group. 1993. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. 11: 909–913. 11 Ohno, R., K. Okada, T. Masaoka, A. Kuramoto, T. Arima, Y. Yoshida, Y. Ariyoshi, M. Ichimaru, Y. Sakai, M. Oguro, Y. Ito, Y. Morishima, S. Yokomaku & K. Ota. 1990. An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8: 1907–1912. 12 Tsuda, H., K. Takatsuki, R. Ohno, T. Masaoka, K. Okada, S. Shirakawa, T. Ohashi, K. Ota & The CPT-11 Study Group on Hematological Malignancy. 1994. Treatment of adult T-cell leukemia-lymphoma with irinotecan hydrochloride (CPT-11). Br. J. Cancer 70: 771–774. 13 Masuda, N., M. Fukuoka, S. Kudoh, Y. Kusunoki, K. Matsui, N. Takifuji, K. Nakagawa, M. Tamanoi, T. Nitta, T. Hirashima, S. Negoro & M. Takada. 1993. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br. J. Cancer 68: 777–782. 14 Kudoh, S., M. Fukuoka, N. Masuda, A. Yoshikawa, Y. Kusunoki, K. Matsui, S. Negoro, N. Takifuji, K. Nakagawa, T. Hirashima, T. Yana & M. Takada. 1995. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn. J. Cancer Res. 86: 406–413. 15 Masuda, N., M. Fukuoka, M. Takada, Y. Kusunoki, S. Negoro, K. Matsui, S. Kudoh, N. Takifuji, K. Nakagawa & S. Kishimoto. 1992. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J. Clin. Oncol. 10: 1775–1780. 16 Masuda, N., M. Fukuoka, S. Kudoh, Y. Kusunoki, K. Matsui, A. Nakagawa, T. Hirashima, M. Tamanoi, T. Nitta, T. Yana, S. Negoro, N. Takifuji & M. Takada. 1994. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J. Clin. Oncol. 12: 90–96. 17 Nakagawa, K., M. Fukuoka, H. Niitani & The CPT-11 Lung Cancer Study Group. 1993. Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12: 335. 18 Fujiwara, Y., M. Yamakido, M. Fukuoka, S. Kudo, K. Furuse, H. Ikegami & Y. Ariyoshi, for The West Japan Lung Cancer Study Group. 1994. Phase II Study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer (SCLC) Proc. Am. Soc. Clin. Oncol. 13: 335. 19 Kudoh, S., N. Kurihara, M. Fukuoka, K. Furuse, H. Ikegami, Y. Ariyoshi, M. Takada & T. Takeda. 1995. A phase II study of irinotecan combined with cisplatin in patients with small-cell lung cancer. Proc. Jpn. Soc. Chest Diseases 33: 272. 20 Shinkai, T., H. Arioka, H. Kunikane, K. Eguchi, Y. Sasaki, T. Tamura, Y. Ohe, F. Oshita, M. Nishio, A. Karato, H. Okamoto, H. Nakashima, H. Ohmatsu, J. Shiraishi, N. Nomura & N. Saijo. 1994. Phase I clinical trial of irinotecan (CPT-11), 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res. 54: 2636–2642. 21 Karato, A., Y. Sasaki, T. Shinkai, K. Eguchi, T. Tamura, Y. Ohe, F. Oshita, M. Nishio, H. Kunikane, H. Arioka, H. Ohmatsu, H. Nakashima, J. Shiraishi & N. Saijo. 1993. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J. Clin. Oncol. 11: 2030–2035. 22 Saijo, N., K. Nishio, N. Kubota, F. Kanzawa, T. Shinkai, A. Karato, Y. Sasaki, K. Eguchi, T. Tamura, Y. Ohe, F. Oshita & M. Nishio. 1994. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy camptothecin: Mechanism of resistance and clinical trials. Cancer Chemother. Pharmacol. 34: S112–S117. 23 Masuda, N., M. Fukuoka, S. Kudoh, K. Matsui, Y. Kusunoki, M. Takada, K. Nakagawa, T. Hirashima, H. Tsukada, T. Yana, A. Yoshikawa, A. Kubo, E. Matsuura, T. Nitta, N. Takifuji, K. Terakawa & S. Negoro. 1994. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J. Clin. Oncol. 12: 1833–1841. 24 Goto, K., T. Nishiwaki, N. Saijo, T. Nakabayashi, Y. Kawakami, A. Fujita, K. Tobise, S. Abe, S. Suzuki, S. Tsuchiya, S. Takahashi, I. Hayashi, K. Noda, Y. Kurita, T. Matsuda, T. Tamura & M. Shimoyama. 1995. A phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small cell lung cancer (NSCLC): Japanese Clinical Oncology Group (JCOG) Trial. Proc. Am. Soc. Clin. Oncol. 14: 362. 25 Ando, M., K. Eguchi, T. Shinkai, T. Tamura, Y. Ohe, N. Yamamoto, Y. Kurata, T. Kasai, H. Ohmatsu, K. Kubota, T. Sekine, S. Hojo, T. Matsumoto, R. Kakinuma, Y. Nishiwaki & N. Saijo. 1996. Phase I study of sequentially administered CPT-11 and VP-16 for metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 26 Yokoyama, A., Y. Kurita, N. Saijo, A. Noda, T. Nakabayashi, T. Tukamoto, S. Yoneda, M. Masuya, K. Kudoh, T. Tamura, T. Shimokata & T. Matsuda. 1996. Phase I-II study of irinotecan (CPT-11) and cisplatin plus concurrent thoracic radiation therapy in stage III non-small cell lung cancer: A Japanese Clinical Oncology Group Trial. Proc. Am. Soc. Clin. Oncol. 27 Sasaki, Y., H. Hakusui, S. Mizuno, M. Morita, T. Miya, K. Eguchi, T. Shinkai, T. Tamura, Y. Ohe & N. Saijo. 1995. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn. J. Cancer Res. 86: 101–110. 28 Ohe, Y., Y. Sasaki, T. Shinkai, K. Eguchi, T. Tamura, A. Kojima, H. Kunikane, H. Okamoto, A. Karato, H. Ohmatsu, F. Kanzawa & N. Saijo. 1992. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84: 972–974. 29 Sasaki, Y., Y. Yoshida, K. Sudoh, H. Hakusui, H. Fujii, T. Ohtsu, H. Wakita, T. Igarashi & K. Ito. 1995. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn. J. Cancer Res. 86: 111–116. 30 Yamamoto, N., T. Tamura, A. Karato, K. Uenaka, K. Eguchi, T. Shinkai, Y. Ohe, F. Oshita, H. Arioka, H. Nakashima, J. Shinkai, M. Fukuda, S. Higuchi & N. Saijo. 1994. CPT-11: Population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. Jpn. J. Cancer Res. 85: 972–977. 31 Sasaki, Y., S. Mizuno, H. Fujii, T. Ohtsu, H. Wakita, T. Igarashi, K. Itoh, I. Sekine, Y. Miyata & N. Saijo. 1995. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38. Jpn. J. Cancer Res. 86: 117–123. 32 Rowinsky, E. K., L. B. Grochow, D. S. Ettinger, E. Sartorius, B. G. Lubejko, T. L. Chen, M. K. Rock & R. C. Donehower. 1994. Phase I and pharmacological study of the novel topoisomerase 1 inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino-Icarbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 54: 427–436. 33 Abigerges, D., G. G. Chabot, J. P. Armand, P. Herait, A. Gouyette & D. Gandia. 1995. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol. 13: 210–221. 34 Rothenberg, M. L., J. G. Kuhn, H. A. Burris, J. Nelson, J. R. Eckardt, M. Tristan-Morales, S. G. Hilsenbeck, G. R. Weiss, L. S. Smith, G. I. Rodriguez, M. K. Rock & D. D. Van Hoff 1993. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11: 2194–2204. 35 Fukuda, M., K. Nishio, F. Kanzawa, H. Ogasawara, T. Ishida, H. Arioka, K. Bajanowski, M. Oka & N. Saijo. 1996. Synergism between cisplatin and topoisomerase I inhibitors, NB506 and SN-38, in human small cell lung cancer cells. Cancer Res. 56: 789–793. 36 Kubota, N., F. Kanzawa, K. Nishio, Y. Takeda, T. Ohmori, Y. Fujiwara, Y. Terashima & N. Saijo. 1992. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun. 188: 571–577. 37 Sasaki, Y., A. Ohtsu, Y. Shimada, K. Ono & N. Saijo. 1994. Simultaneous administration of CPT-11 and fluorouracil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J. Natl. Cancer Inst. 86: 1096–1098. 38 Mitsui, I., E. Kumazawa, Y. Hirota, M. Aonuma, M. Sugimori, S. Ohkushi, K. Uoto, A. Ejima, H. Terasawa & K. Sato. 1995. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn. J. Cancer Res. 86: 776–782. 39 Kanzawa, F., K. Nishio, N. Kubota & N. Saijo. 1995. Antitumor activities of a new indolecarbozole substance, NB-506. and establishment of a new NB-506-resistant cell lines, SBC-3/NB. Cancer Res. 55: 2806–2813. Citing Literature Volume803, Issue1The Camptothecins: From Discovery to the PatientDecember 1996Pages 292-305 ReferencesRelatedInformation